Predictors of predominant Lupus Low Disease Activity State (LLDAS-50).
Adult
Black or African American
Antibodies, Antinuclear
/ blood
Disease Progression
Female
Humans
Hydroxychloroquine
/ therapeutic use
Logistic Models
Lupus Erythematosus, Systemic
/ diagnosis
Male
Maryland
Middle Aged
Multivariate Analysis
Prospective Studies
Risk Assessment
/ methods
Severity of Illness Index
Ethnicity
LLDAS
hydroxychloroquine
low disease activity state
systemic lupus erythematosus
Journal
Lupus
ISSN: 1477-0962
Titre abrégé: Lupus
Pays: England
ID NLM: 9204265
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
pmc-release:
01
12
2019
pubmed:
7
11
2019
medline:
17
4
2020
entrez:
8
11
2019
Statut:
ppublish
Résumé
The Lupus Low Disease Activity State (LLDAS) is a potential treat to target goal in systemic lupus erythematosus (SLE). SLE patients in LLDAS for more than half of the observation time have about a 50% lower risk of new organ damage and have reduced mortality. We identified predictors of being in LLDAS ≥50% of the observation time. A total of 2228 SLE patients who had at least three clinical visits were included. Percentage of time in LLDAS was calculated based on the proportion of days under observation. LLDAS-50 was defined as being in LLDAS for ≥50% of the observation time. We used the stepwise selection procedure in logistic regression to identify predictors of LLDAS-50. A total of 1169 (52.5%) SLE patients, but only 37.6% of African Americans, achieved LLDAS-50. In the multivariable model, African American ethnicity, hypocomplementemia, serositis, renal activity, arthritis, anti-RNP, anti-dsDNA, vasculitis, malar rash, discoid rash, thrombocytopenia, and immunosuppressive use were negative predictors of LLDAS-50. Older age at diagnosis, longer disease duration, higher education level, and greater percentage of time taking hydroxychloroquine remained positive predictors of LLDAS-50. In this large cohort, only 52.5% achieved LLDAS-50. This proportion was even less in African Americans. A higher percentage of time taking hydroxychloroquine was a modifiable positive predictor of LLDAS-50. Anti-RNP, anti-dsDNA, and low complement were negatively associated with LLDAS-50. Our findings further emphasize the importance of inclusion of African Americans in clinical trials and hydroxychloroquine adherence in both clinical practice and clinical trials.
Identifiants
pubmed: 31694446
doi: 10.1177/0961203319886028
pmc: PMC6872940
mid: NIHMS1541208
doi:
Substances chimiques
Antibodies, Antinuclear
0
Hydroxychloroquine
4QWG6N8QKH
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1648-1655Subventions
Organisme : NIAMS NIH HHS
ID : R01 AR043727
Pays : United States
Organisme : NIAMS NIH HHS
ID : R01 AR069572
Pays : United States
Références
Ann Rheum Dis. 2018 Jan;77(1):104-110
pubmed: 28970217
Arthritis Rheumatol. 2018 Nov;70(11):1790-1795
pubmed: 29806142
Medicine (Baltimore). 2006 May;85(3):147-56
pubmed: 16721257
J Rheumatol. 2015 Nov;42(11):2092-7
pubmed: 26428205
Arthritis Rheum. 2013 Mar;65(3):753-63
pubmed: 23203603
Ann Rheum Dis. 2006 Nov;65(11):1500-5
pubmed: 16627544
Medicine (Baltimore). 2010 Jan;89(1):62-7
pubmed: 20075706
Lancet. 2019 Feb 2;393(10170):402-403
pubmed: 30712893
Lupus Sci Med. 2017 May 22;4(1):e000200
pubmed: 29177060
Ann Rheum Dis. 2019 May;78(5):629-633
pubmed: 30679152
Arthritis Care Res (Hoboken). 2019 Mar 1;:null
pubmed: 30821926
Arthritis Res Ther. 2016 Nov 9;18(1):260
pubmed: 27829463
Arthritis Rheum. 1992 Jun;35(6):630-40
pubmed: 1599520
Arthritis Rheum. 2013 Aug;65(8):2143-53
pubmed: 23754628
N Engl J Med. 2005 Dec 15;353(24):2550-8
pubmed: 16354891
Ann Rheum Dis. 2019 Jun;78(6):736-745
pubmed: 30926722
Arch Intern Med. 1990 Apr;150(4):849-53
pubmed: 2327845
Arthritis Rheum. 1998 Jul;41(7):1173-80
pubmed: 9663472
Rheumatology (Oxford). 2004 Aug;43(8):1039-44
pubmed: 15161983
Lupus Sci Med. 2018 Nov 2;5(1):e000287
pubmed: 30538818
Rheum Dis Clin North Am. 2000 May;26(2):199-213, v
pubmed: 10768209
Ann Rheum Dis. 2007 Sep;66(9):1168-72
pubmed: 17389655
Nat Rev Rheumatol. 2016 Oct;12(10):605-20
pubmed: 27558659
Arthritis Rheum. 2012 Aug;64(8):2677-86
pubmed: 22553077
Arthritis Rheum. 2005 May;52(5):1473-80
pubmed: 15880829
Ann Rheum Dis. 2016 Dec;75(12):e78
pubmed: 27797752
Arthritis Res Ther. 2017 Mar 20;19(1):62
pubmed: 28320433
Arthritis Rheum. 1996 Mar;39(3):363-9
pubmed: 8607884
Rheumatology (Oxford). 2018 Feb 1;57(2):337-344
pubmed: 29121273
Arthritis Rheum. 1997 Sep;40(9):1725
pubmed: 9324032
J Rheumatol. 1992 Jan;19(1):53-9
pubmed: 1556700
Arthritis Rheum. 1982 Nov;25(11):1271-7
pubmed: 7138600
Lupus Sci Med. 2018 Feb 27;5(1):e000234
pubmed: 29531772
Lupus. 2002;11(3):152-60
pubmed: 12004788
Ann Rheum Dis. 2016 Sep;75(9):1615-21
pubmed: 26458737
Lupus. 2002;11(2):95-101
pubmed: 11958584
Arthritis Rheum. 1999 Dec;42(12):2682-8
pubmed: 10616018
Lupus. 2006;15(9):577-83
pubmed: 17080912
Lupus. 2018 Apr;27(5):722-727
pubmed: 29087260
Lupus. 2010 May;19(6):727-33
pubmed: 20118158
Arthritis Rheum. 1990 May;33(5):634-43
pubmed: 2346519
Lupus. 1999;8(3):197-209
pubmed: 10342712
Rheumatology (Oxford). 2017 Jan;56(1):121-128
pubmed: 27803306
Immunol Rev. 2010 Jan;233(1):126-45
pubmed: 20192997
N Engl J Med. 1991 Jan 17;324(3):150-4
pubmed: 1984192
Ann Rheum Dis. 2018 May;77(5):706-713
pubmed: 29420200
Lupus. 2002;11(3):161-7
pubmed: 11999880